GenSight BIOLOGICS

CORPORATE PRESENTATION

A leading gene therapy biotechnology company

www.gensight-biologics.com

Disclaimer

This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the “Company”), including with respect to the anticipated future performance of the Company, its subsidiaries and affiliates, and the market in which they operate. They include all matters that are not historical facts. These forward-looking statements can be identified by the use of forward-looking terminology including the terms “developments,” “estimates,” “expects,” “intends,” “may,” “milestones,” “potential,” “value,” “time to market,” “targeting,” “on track,” “planned,” “will,” “move to,” or other variations or comparable terminology, or by discussions of strategy and funding, as well as the Company’s, its subsidiaries’ and affiliates’ technology, and are based on financial and non-financial information, including projections as to the future regulatory situation and other information and assumptions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company’s control. Therefore, actual results, the financial condition, performance or achievements of the Company, its subsidiaries and affiliates or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this forward-looking statement, and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. The Company, its subsidiaries and affiliates disclaim any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company’s expectations with regard thereto, or any events, or changes in conditions or circumstances on which any such statement, forecast or estimate is based.

Corporate Overview

Clinical-stage gene therapy company

- Focused on severe retinal degenerative pathologies leading to blindness as well as CNS diseases
- Well positioned to advance disruptive gene therapy technologies in ophthalmology to commercialization

Two disruptive technology platforms

- Mitochondrial targeting sequence (MTS)
- Optogenetics

Lead projects target:

- GS010 - Leber Hereditary Optic Neuropathy (Phase III)
- GS030 - Retinitis pigmentosa and dry-AMD (Phase I/II)

Listed on Euronext Paris (SIGHT)

- Established in 2012, IPO in July 2016 (EUR45m)
- GenSight Biologics Inc incorporated in the US in May 2017

Executive Team

Bernard Gilly
Chief Executive Officer

PIXIUM VISION (Since 2011)
Chairman of the Board, Founder

FOVEA PHARMA (2005-2009)
Chairman & CEO – sold to Sanofi

SOFINNOVA PARTNERS (2000-2005)
Managing Partner

TRANSGENE (1992-2000)
Chairman & CEO

Ph.D. in biology and bio-economics

Thomas Gidoin
Chief Financial Officer

DBV TECHNOLOGIES (2012-2015)
VP of Finance

IPSEN (2008-2011)
UK Operations Controller (London)
Senior Financial Analyst (Paris)

ERNST & YOUNG (2007-2008)
Auditor

Barrett Katz
Chief Medical Officer

MONTEFIORE MED CENTER & A. EINSTEIN COLLEGE OF MEDICINE, NY, USA (2011-2017)
Prof. of Ophthalmology, Neurology and Neurosurgery

DANUBE PHARMA (2009-2011)
CEO

FOVEA PHARMA (2007-2009)
CMO

EYETECH (2005-2007)
VP of Medical Affairs and Strategy

MD, Board-certified ophthalmologist & neurologist

Degenerative retinal diseases

GenSight targets 3 areas of unmet needs: LHON, RP & DRY AMD

PHOTORECEPTOR CELLS TRANSFORM LIGHT INTO ELECTRIC SIGNALS IN THE EYE



ELECTRIC SIGNALS ARE SENT TO THE VISUAL CORTEX OF THE BRAIN VIA THE GANGLION CELLS FORMINGTHE OPTIC NERVE



LEBER HEREDITARY OPTIC NEUROPATHY (LHON)

RETINITIS PIGMENTOSA (RP)
GEOGRAPHIC ATROPHY
(Late stage form ofAge-Related Macular Degeneration - AMD)

Source: Company

Gene therapy in the eye - Methodology

1. Genetic disorders and aging are responsible for retinal degenerative diseases that lead to blindness

2. Therapeutic gene is packaged in a virus vector (AAV)

   AAV is injected into the eye (intravitreal or subretinal)

3. AAV vector expresses a therapeutic protein in retinal cells

   It enables the retina to regain lost function



Source: Company

Advantages of gene therapy in ophthalmology

THE EYE: STRATEGIC TARGET

- No approved curative treatments for retinal degenerative diseases
- Immune privilege, closed system
- Easy access and ability to get gene to target cells
- Limited number of retinal cells
- Long-term expression of transduced gene due to low turnover rate of retinal cells

AAV: SUCCESSFUL IN RETINA

- Proven safety and proof of effect in humans
- Efficient transduction of retinal cells
- No need to screen patients for Nab before treatment
- Validated manufacturing process



NO OTHER APPROVED THERAPEUTIC APPROACHES

- Genetic replacement therapy for diseases caused by single gene mutations (LHON)
- In-situ insertion of therapeutic gene to stimulate sight in patients with severe vision loss due to multiple causes, such as RP and AMD

Source: Company

Pipeline: solid and advanced product portfolio in ophthalmic gene therapy

Technology	Product Candidate	Indication	Research	Preclinical	Phase I/II	Phase III	Registration	Next Expected Events
MTS PLATFORM	**GS010** *(FDA & EMA Orphan Drug Designation)*	LHON ND4						REVERSE: Phase III top-line data reported in April 2018 RESCUE: Phase III top-line data expected in Q1 2019 REFLECT*: Phase III recruitment ongoing, top-line data expected in Q2 2020
	GS011	LHON ND1						Initiate preclinical studies following GS010 Phase III clinical data
	Undisclosed Mitochondrial Target	**Undisclosed**						--
OPTOGENETICS	**GS030** *(FDA & EMA Orphan Drug Designation)*	RP						PIONEER: First subject in ongoing Phase I/II clinical trial treated in October 2018 Report interim data one year after last subject treated
	GS030	Dry AMD & Geographic Atrophy						--

* Conducting this trial under a special protocol assessment with the FDA

Lead candidate, GS010, is expected to be 12 months away from MAA submission in Europe

Note: Please refer to the 2017 Registration Document for a detailed description of regulatory strategy.

GS010

Fully enrolled ongoing Phase III for our lead product candidate dedicated to Leber Hereditary Optic Neuropathy (LHON)

GenSight's proprietary gene sequencing encapsulated in AAV



1. Transduction of retinal cell with replacement mitochondrial gene
2. Transcription of replacement mitochondrial gene in the nucleus
3. Delivery of replacement gene mRNA to polysomes located at the mitochondrial surface
4. Synthesis, translocation and proper localization of replacement mitochondrial protein

The only technology that permits missing mitochondrial proteins to be ***actively*** shuttled into the mitochondrion to restore energy production

LHON: the most common mitochondrial disease causing bilateral blindness at the prime of life







Image source: illustrated from Newamn NJ et al., Am J Ophthalmom. 141(6), 1061-1067,2006



Image source: illustrated from Barboni et al Natural History of Leber's Hereditary Optic Neuropathy: An OCT Study

Incidence	0.15/100,000
Prevalence	1/31k-40k
Blindness	15-35y

- **Orphan maternally inherited mitochondrial disease**
- **Painless sudden loss of central vision** in the 1st eye with 2nd eye sequentially impaired: **symmetric disease with poor visual recovery**
- **Thinning of the Ganglion Cell Layer** occurs after the onset of vision loss and stabilizes at approximately 6 months
- **97%** of patients have bilateral involvement < 1 year / 25% of cases are simultaneous
- **Targets ND4** which accounts for ~75% of LHON in North America & Europe

RESCUE & REVERSE Phase III trials: time based strategy

Phase III Trials

RESCUE
onset of disease
≤ 6 months

&

REVERSE
onset of disease
6 months to ≤ 1 year

- **Initiation:** 4Q 2015 (1st patient in February 2016)
- **39 patients in RESCUE** (recruitment completed in July 2017)
- **37 patients in REVERSE** (recruitment completed in February 2017)
- **Randomized (one eye treated vs. sham), double-masked, sham-controlled, multi-center**

One eye of each patient randomized to GS010 or sham



Endpoints at 48 weeks

Primary:

- Mean Difference in ETDRS of treated eyes compared to eyes receiving sham injection (LogMAR used for statistical analysis)

Secondary:

- Measure vision gain, vision stabilization, or reduction in vision decline
- Best or worst eyes vs. sham
- Responders analysis:
  - Gain from baseline of 15 or more ETDRS letters

    OR
  - Snellen acuity > 20/200
- SD-OCT, visual field, color and contrast vision

Source: Company

REVERSE Data at 72 Weeks

Clinically meaningful improvement of visual acuity

- A clinically meaningful improvement of +15 ETDRS letters reported in treated eyes
- A continuous bilateral improvement from Baseline to Week 72



REVERSE Data at 72 Weeks

Clinically meaningful improvement of contrast sensitivity

- **Contrast sensitivity** as determined by Pelli-Robson low contrast testing increased in both eyes from baseline to week 72:

  Treated eyes: +0.21 LogCS
  Untreated eyes: +0.15 LogCS

- Proportion of treated eyes that achieved a **clinically meaningful improvement of at least 0.3 LogCS** was statistically significantly higher than that of sham-treated eyes:

  Treated eyes: 45.9%
  Untreated eyes: 24.3%

  p=0.0047

REVERSE Data at 72 Weeks

Preservation of the structure of the retina in treated eyes

- SD-OCT demonstrated statistically significant relative preservation of both retinal ganglion cells and retinal fiber layer in treated eyes vs. untreated eyes

  - **Change in retinal ganglion cell macular volume measured from baseline to week 72:**

    Treated eyes: no loss

    Untreated eyes: -0.044mm^3

    p=0.0060

  - **Change thickness of the temporal quadrant and papillomacular bundle of the retinal nerve fiber layer from baseline to week 72:**

    Treated eyes: -1.6 µm

    Untreated eyes: -3.6 µm

    p=0.0521

- Sustained preservation of LHON-relevant retinal anatomy in treated eyes further demonstrates the neuroprotective effect of GS010

REVERSE Data at 72 Weeks

Favorable safety and tolerability profile

- GS010 reported to be well-tolerated
- Ocular adverse events most frequently reported in the therapy group were mainly related to the injection procedure
- Occurrence of intraocular inflammation (accompanied by elevation of intraocular pressure in some patients) responsive to conventional treatment and without sequelae
- No withdrawals from the trial

REFLECT Phase III trial: bilateral treatment

Phase III Trial

- **Initiation:** 4Q 2017 (1st patient treated in March 2018)
- **90 patients** planned (45 in each group) with vision loss ≤ 1 year
- **Randomized (two eyes treated vs. one eye treated + placebo in the other eye), double-masked, placebo-controlled, multi-center**
- **Conducted under a Special Protocol Assessment (SPA) from the FDA**

Endpoints at 48 weeks

Primary:

Difference in change of vision compared to baseline between GS010 Treatment vs. Placebo in second affected/not yet affected eyes (LogMAR visual acuity used for statistical analysis)

Secondary:

- Best Corrected Visual Acuity at 2 years
- Spectral domain OCT biomarkers
- Humphrey visual field analysis
- Pelli Robson Low Vision Contrast Sensitivity
- Quality of life assessments



Confirmatory Phase III study to assess safety and efficacy of a bilateral injection of GS010

GS010: an accelerated path to market



FPFV: First Patient First Visit
LPFV: Last Patient First Visit
LPLV: Last Patient Last Visit

Objective: European marketing authorization submission for GS010 in Q4 2019

(1) FDA approval is expected to be conditional upon the initiation of a trial to evaluate bilateral dosing. Current discussions with the FDA remain ongoing. Please refer to the 2016 Registration Document for a detailed description of regulatory strategy.

GS030

Second lead product candidate targeting photoreceptor degenerative diseases (RP/AMD)

RP / AMD: degenerative diseases of photoreceptors leading to blindness

Retinitis Pigmentosa (RP)

- Blinding genetic disease with multiple mutations (+100 genes)
- Sequential photoreceptor degeneration
- Slow & irreversible evolution leading to blindness



Incidence	15K-20K / year
Prevalence	350K-400K (1.5 M worldwide)
Blindness Occurence	40-45 years old

Age-Related Macular Degeneration (AMD)

- Onset of AMD: 55 to 60 years of age
- Early form: dry-AMD that evolves with aging to late AMD
- Late AMD can either be:
  - Neovascular form (wet-AMD)
  - Geographic atrophy
- Prevalence of geographic atrophy increases with age from 3.5% over 75 years to 22% over 90 years

Incidence of AMD	350k – 400k / year
Prevalence of Late AMD	1.47% with 0.81% geographic atrophy in at least one eye
Blindness Occurrence from Late AMD	250 000 with geographic atrophy accounting from 10 to 20% of blind patients

Optogenetics: gene therapy with photosensitive protein

Transferring a gene encoding light-sensitive protein to retinal ganglion cells to restore photoreceptor function in cells that are still wired to the visual cortex



Restore photoreceptor function in cells by training RGCs to act as photoreceptors

GS030: stimulating the eye with light through gene therapy

1

AAV2.7m8



+ ChrimsonR



Massachusetts Institute of Technology

ADVERUM BIOTECHNOLOGIES

GenSight BIOLOGICS

UPMC

Gene therapy transfer of light sensitive protein

2



Expression in retinal ganglion cells

3



retinal output sent to brain for image processing

Stimulation with optoelectronic device
External visual interface transforms external light stimuli into signal that activates the transduced retinal ganglion cells

Source: Company

GS030: activation and stimulation of retinal ganglion cells, providing visual information to the higher visual centers

Irradiance-firing relationship in monkey retina



Expression of ChrR-tdT in midget cells of monkey perifovea



Light-induced visual evoked cortical responses in rats



GS030 is well tolerated in non-human primates and 590 nm LED light stimulation is safe in *rd1* blind mice







Toxicity study of GS030 product in non-human primates (n=32)

Bilateral IVT administration with **vehicle** *vs* **7.21x10^{10} VG/eye *(low dose)*** *vs* **7.84x10^{11} VG/eye *(high dose)*** in 100 µL

Ophthalmology	• **Dose-dependent ocular inflammation** in the anterior segment and vitreous, improving/resolving from Month 2 up to Month 6 • **Not associated with any retinal tissue destruction or functional changes** • **No or very slight residual inflammation in all animals at 6 months** (self-resolution, no treatment before or after injection)
Histopathology	• **Eye tissues: dose-dependent minimal mononuclear cell infiltration** • **Other tissues: no histological findings**
Immunogenicity (anti-AAV2 NAb)	• **Expected humoral immune response in serum** starting at Day 15, tended to decrease at Week 13 then sustained up to Month 6 • **Dose-dependent local immune response** in aqueous humor and vitreous

Local tolerance of GS030 product avec light exposure in *rd1* blind mice (n=36)

Bilateral IVT administration with **vehicle** *vs* **7.84x10^{11} VG/eye** in 1 µL

590 nm LED light at **1.4×10^{16}** *vs* **1.7×10^{17} photons/cm^2/s** *vs* **ambient room light**

Local tolerance (Ophthalmology & Histology)	• **No ophthalmic findings related to GS030-DP or LED light** • **No GS030-DP-related and no LED-related microscopic findings in the retina** • Transient corneal edema & lens opacity linked to anesthesia procedure
ChrimsonR-tdTomato expression	**Good expression of ChrimsonR-tdTomato in retinas and optic nerves**

Source: Company

PIONEER Phase I/II clinical trial: A First-in-Man study

Study design



- **First-in-man**, dose-escalation safety study, multi-center
- **Study population:** end-stage non-syndromic RP (vision < Counting Fingers)
- **Primary analysis:** Safety at 1 year
- Single intra-vitreal injection in the **worst affected** eye
- Decision to increase the dose taken by a DSMB

First patient treated in October 2018 at the Moorfields Eye Hospital in the UK

Source: Company

GS030: CMC progress & Regulatory interactions

CMC

- **Manufacturing process developed up to 25L**
  - Toxicology batch produced at 25L scale
  - Drug Substance titers (> 2E13 vg/ml) and characteristics in line with expectations
  - Scale up to 100L batch successful
- **Manufacturing process successfully transfered to GMP**
  - GMP clinical supply ready
  - 100L GMP batches manufactured
- **Potency assay**
  - Development completed
  - Transfer in progress

Regulatory

- **Orphan Drug Designation** granted in the US and in Europe
- **Active strategy & interactions with US and EU Agencies** to obtain advice on preclinical package to support FIM and exploit the existing process of expedited programs
- **CTA approved in the UK and in France**
- **IND released by FDA in the US**

Key expected development milestones for GS030



ODD: Orphan Drug Designation
CTA: Clinical Trial Application
EMA: European Medicines Agency
IDE: Investigational Device Exemption

First patient treated in October 2018 at the Moorfields Eye Hospital in the UK

Building a high strategic value

Curing blindness represents major market opportunity



Favorable reimbursement conditions:

- Gene therapy in ophthalmology for rare diseases could be considered **similar to organ transplants for payers**
- Blindness imposes a **high burden** to health systems
  - Total blindness costs exceed tens of billions USD per annum
- **Absence of curative treatments**
  - Increasing pressure from patients and patients associations

Geographical Split – Blind people in major markets



Source: WHO, IAPB-VISION2020, NORC-Univ. of Chicago / The Economic Burden of Vision Loss and Eye Disorders in the United States, 2014.

Pricing and prevalence: organ transplant / gene therapy



Orphan therapies and transplants: a relevant pricing benchmark

Source: Nature Biotechnology, Volume 33, Number 9, September 2015: The payers' perspective on gene therapy.

Potential applications of GenSight technology platforms

Current focus

- LHON
- RP
- AMD

GenSight BIOLOGICS

Potential applications



MTS PLATFORM

- Other LHON
- Dominant Optic Atrophy
- NARP Leigh Syndrome
- Amyotrophic Lateral Sclerosis
- Parkinson's

OPTOGENETICS PLATFORM

SENSORIAL	NON-SENSORIAL
Dry-AMD	Vagus Nerve Stimulation
Congenital Deafness	

Ability to leverage technology platforms and significant expertise to expand the pipeline in ophthalmology and other neurodegenerative disorders

GenSight Biologics
Key financial information

Financing history
- March 2013 – Series A round – €20m
- June 2015 – Series B round – €32m
- July 2016 – Euronext IPO – €45m
- June 2017 – PIPE – €22m

Listed on Euronext Paris (SIGHT)
- Established in 2012, IPO in July 2016

Recognition from Blue-Chip specialist investors
- Perceptive, Fidelity, Abingworth, Versant, JP MorganAM and others

Analyst coverage
- Oddo & Cie – *Pierre Corby* (FR)
- Gilbert Dupont – *Jamila El Bougrini* (FR)
- Chardan – *Gbola Amusa* (US)

Cash position
(as of Sep 30, 2018)

€39.2m

Number of outstanding shares

24.8m

Appendix

REVERSE Topline Data at 48 Weeks

Clinically meaningful improvement of visual acuity

- A clinically meaningful improvement of +11 ETDRS letters reported in the 37 subjects in both eyes



REVERSE Topline Data at 48 Weeks

Preservation of the structure of the retina in treated eyes

- SD-OCT demonstrated statistically significant relative preservation of both retinal ganglion cells and retinal fiber layer in treated eyes vs. untreated eyes

  - **Change in retinal ganglion cell macular volume measured from baseline to week 48:**

    Treated eyes: no loss
    Untreated eyes: -0.038mm3

  - **Change thickness of the temporal quadrant and papillomacular bundle of the retinal nerve fiber layer from baseline to week 48:**

    Treated eyes: -0.6 µm
    Untreated eyes: -3.4 µm

REVERSE Topline Data at 48 Weeks

Favorable safety and tolerability profile

- GS010 reported to be well-tolerated
- Ocular adverse events most frequently reported in the therapy group were mainly related to the injection procedure
- Occurrence of intraocular inflammation (accompanied by elevation of intraocular pressure in some patients) responsive to conventional treatment and without sequelae
- No withdrawals from the trial

REVERSE Additional Data & *Post Hoc* Analyses at 48 Weeks

- **Contrast sensitivity** as determined by Pelli-Robson low vision testing almost doubled in the GS010 treated eyes compared to sham treated eyes from baseline to week 48:

  Treated eyes: +0.20 LogCS
  Untreated eyes: +0.08 LogCS

- *Post hoc* analyses revealed trends that suggest **GS010 may have a larger positive impact on the visual acuity of patients at relatively less advanced or severe stages of the disease:**

  - **Subjects who entered study with better vision (on-chart best) tended to have better clinical outcomes.** At week 48, in on chart best-seeing eyes, GS010 treated eyes gained on average +12 ETDRS letters (-0.236 LogMAR) compared to +4 ETDRS letters (-0.075 LogMAR) in sham treated eyes.

  - **Subjects whose vision loss was less than 9 months tended to have better clinical outcomes.** 75% of GS010-treated eyes that showed a trend in visual acuity improvement at week 48 had vision loss for less than 9 months at time of treatment administration.

  - **Subjects who were younger (< 21 years) at enrollment tended to have better clinical outcomes**

Phase I/II: Design & Safety Results



- First-in-man, dose-escalation safety study, single center (Paris XV-XX)
- Chronic LHON ND4 patients with < 20/200
- Single intra-vitreal injection in the **worst affected** eye
- Decision to increase the dose taken by a DSMB

Results: Successfully Met Primary Endpoints

- **Excellent systemic safety**
- **No dose-related toxicity**
- **Mostly mild, well tolerated, ocular side effects that are responsive to standard therapy**
- **Typical immune responses**

Source: Company

Phase I/II follow-up

Sustained improvement after 2.5 years in patients with less than 2 years of vision loss

Mean change from Baseline



Subgroup 1 (n=5)
Vision loss duration ≤ 2 years and Baseline LogMAR ≤ 2.79
(ie excludes "hand motion" patients, in accordance with the Phase III protocol)

Illustration of visual benefit for patient



Source: Company

Phase I/II follow-up

Sustained improvement after 2.5 years in patients with less than 2 years of vision loss

ETDRS letters (LogMAR) Visual Acuity change from baseline **Δ TE vs UTE**	**1.0 year**	**1.5 year**	**2.0 years**	**2.5 years**
All patients (n = 14)	+3 letters (-0.06)	+8 letters (-0.16)	+0 letters (-0.00)	+7 letters (-0.14)
Patients with ≤ 2y disease duration (n = 5)*	+17 letters (-0.34)	+20 letters (-0.40)	+14 letters (-0.28)	+15 letters (-0.30)

Note (*): Excludes “hand motion” patients, in accordance with the Phase III protocol.

Trends of improved visual acuity in patients with less than 2 years of vision loss

Phase I/II follow-up

Strong trends validate and inform our Phase III design

Symptom duration impacts magnitude of treatment effect

- VA beneficial positive trends after 2.5 years in patients ≤ 2y of vision loss with a clinically significant improvement (≥ 15 ETDRS letters)
- Color vision beneficial trends at week 48 in patients with ≤ 2y symptom duration, confirmed with subjective outcome from patients

Baseline vision status at treatment impacts magnitude of treatment effect

- Observed in visual field & color vision tests

Analysis supports protocol strategy for phase III

- Population divided by time from onset
- Effect analyzed on better seeing eye

> **Now I can see if a traffic light is red or green. In the subway, I can read the names of stations with large letters. I have better autonomy.**

"Phase 1 Patient"

Our MTS Sequence enhances growth and ATP synthesis in LHON Fibroblasts

Fibroblasts	Survival rate on galactose	Rate of ATP synthesis on galactose
Control	100%	100%
LHON (mutated ND4)	8%	14%
LHON + MTS1	12.7%	56%
LHON + MTS1 & MTS2	**54.3%**	**84%**

Both MTS1 and MTS2 sequences are necessary for an efficient transfer of the mitochondrial protein

From patent WO 2006/117250 A2

GS010 / GS030: IP and market exclusivity timelines

Products	Components	Licenses	Associated IP	Patent Term
GS010	Mitochondrial Targeting Sequence	Worldwide exclusive license in ophthalmology Non exclusive license outside of ophthalmology Inserm	MTS/3'UTR mitochondrial trafficking IP	2026 + PTE/SPC* of 5 years
		ORPHAN STATUS - MARKET EXCLUSIVITY EU: 10 YEARS + 2 YEARS FOR PEDIATRIC US: 7 YEARS IN THE US + 6 MONTHS FOR PEDIATRIC		
GS030	Light Sensitive Protein	Worldwide exclusive license in ophthalmology and non-exclusive license outside of ophthalmology Massachusetts Institute of Technology	ChrimsonR IP	2032 + PTE/SPC* of 5 years
	Engineered AAV	Worldwide exclusive license in Optogenetics AVALANCHE	Vector AAV2 7m8 IP	2032
		ORPHAN STATUS - MARKET EXCLUSIVITY EU: 10 YEARS + 2 YEARS FOR PEDIATRIC US: 7 YEARS IN THE US + 6 MONTHS FOR PEDIATRIC		

Note: *Patent Term Extension/Supplementary Protection Certificate

2017 Financial Statements

P&L (IFRS consolidated)

In million Euros	2016	2017
Operating income	**3.0**	**3.7**
Research & Development expenses	(18.5)[1]	(18.7)[2]
Sales & Marketing expenses	-	(0.8)
General & Administrative expenses	(6.5)[1]	(8.2)[2]
Operating profit (loss)	**(22.0)**	**(24.0)**
Financial income (loss)	(0.1)	(0.1)
Net income (loss)	**(22.1)**	**(24.1)**
Excl. non-cash share-based compensation expenses	*(17.4)*	*(19.3)*

Notes:
(1) Includes €1.8m and €2.8m of non-cash share-based compensation expenses (IFRS2) in R&D and G&A, respectively, in 2016.
(2) Includes €1.5m and €3.2m of non-cash share-based compensation expenses (IFRS2) in R&D and G&A, respectively, in 2017.

2017 Financial Statements

Balance Sheet (IFRS consolidated)

In million Euros	As of December 31 2016	2017
Non-current assets	1.2	1.4
Cash and cash equivalents	54.0	55.4
Short term investments	–	–
Other current assets	4.1	5.4
TOTAL ASSETS	**59.2**	**62.2**
Shareholders' equity	**53.3**	**55.0**
Non-current liabilities	3.0	3.1
Current liabilities	2.9	4.1
Total liabilities	**5.9**	**7.2**
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	**59.2**	**62.2**

2017 Financial Statements

Cash Flows Statements (IFRS consolidated)

In million Euros	2016	2017
Net cash flows from operating activities	(19.6)	(18.8)
Net cash flows from investment activities	(0.2)	(0.7)
Net cash flows from financing activities	43.7(1)	20.9(2)
Increase/(decrease) in cash and cash equivalents	**23.9**	**1.5**
Cash and cash equivalents at the close of the period	**54.0**	**55.4**

Notes:
(1) Includes €41.4m net proceeds from our Initial Public Offering (IPO) on Euronext Paris in July 2016.
(2) Includes €20.7m net proceeds from our Private Placement (PIPE) on Euronext Paris in June 2017.